Literature DB >> 24583709

Radiofrequency ablation for pulmonary metastases from gastrointestinal cancers.

Yoshifumi Baba1, Masayuki Watanabe, Naoya Yoshida, Koichi Kawanaka, Yasuyuki Yamashita, Hideo Baba.   

Abstract

The lung is one of the most common targets of metastases from gastrointestinal (GI) cancers. Surgical treatment (i.e., metastasectomy) is an accepted therapeutic option for pulmonary metastases from GI cancers. However, surgery may be contraindicated in advanced stages of cancer, compromised lung function, and/or comorbidities. This issue has prompted the search for innovative and less invasive ways of treating pulmonary metastases. Image-guided radiofrequency ablation (RFA) has attracted great interest as a minimally invasive approach against intrathoracic malignancies. In this technique, radiofrequency energy is applied via a needle electrode inserted into the target tissue. As the cells are agitated by the applied energy, they release heat, causing denaturation and cell death. Recently, this technique has been used on patients with pulmonary metastatic disease arising from GI cancers such as colorectal cancer, esophageal cancer, and hepatocellular carcinoma, as well as on patients with primary lung cancer. The present review updates the clinical outcomes and advances in RFA therapy of lung metastases from GI cancers.

Entities:  

Mesh:

Year:  2014        PMID: 24583709     DOI: 10.5761/atcs.ra.13-00343

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  8 in total

1.  Surgery and ablative techniques for lung metastases in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial: is there equivalence?

Authors:  Tom Treasure
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  A prospective clinical trial of radiofrequency ablation for pulmonary metastases.

Authors:  Yizong Wang; Xueguan Lu; Ying Wang; Wentao Li; Guodong Li; Jun Zhou
Journal:  Mol Clin Oncol       Date:  2015-03-06

3.  Gut microbial dysbiosis and its association with esophageal cancer.

Authors:  Hafiz Muhammad Ishaq; Imran Shair Mohammad; Kiran Sher Muhammad; Huan Li; Rao Zahid Abbas; Zia Ud Din Sindhu; Shakir Ullah; Yang Fan; Abbas Sadiq; Muhammad Asif Raza; Riaz Hussain; Hafiz Muhammad Arshad; Iahtasham Khan; Muhammad Umair Waqas; Aziz Ul-Rahman; Riffat Yasin; Atif Rehman; Rana Waseem Akhtar; Jiru Xu
Journal:  J Appl Biomed       Date:  2021-02-03       Impact factor: 1.797

4.  Oral microbiota may predict the presence of esophageal squamous cell carcinoma.

Authors:  Zongdan Jiang; Jun Wang; Xuetian Qian; Zhenyu Zhang; Shukui Wang
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-12       Impact factor: 4.322

5.  Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma.

Authors:  Zongdan Jiang; Jun Wang; Ziyang Shen; Zhenyu Zhang; Shukui Wang
Journal:  Front Cell Infect Microbiol       Date:  2021-11-11       Impact factor: 5.293

Review 6.  Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT.

Authors:  Meritxell Molla; Julen Fernandez-Plana; Santiago Albiol; Constantino Fondevila; Ivan Vollmer; Carla Cases; Angeles Garcia-Criado; Jaume Capdevila; Carles Conill; Yliam Fundora; Carlos Fernandez-Martos; Estela Pineda
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

Review 7.  Value of ablation therapy in the treatment of lung metastases.

Authors:  Han Qi; Weijun Fan
Journal:  Thorac Cancer       Date:  2017-11-29       Impact factor: 3.500

Review 8.  Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications.

Authors:  Yoshifumi Baba; Masaaki Iwatsuki; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  Ann Gastroenterol Surg       Date:  2017-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.